immatics biotechnologies GmbH
immatics biotechnologies GmbH
Your view on IMTXW
Overview
What the company does, where it operates, and who runs it.
About immatics biotechnologies GmbH
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Harpreet Singh
- Headquarters
- Paul-Ehrlich-Strasse 15, Tübingen, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Harpreet Singh
- Headquarters
- Paul-Ehrlich-Strasse 15, Tübingen, US
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for immatics biotechnologies GmbH, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for immatics biotechnologies GmbH. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for immatics biotechnologies GmbH. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for immatics biotechnologies GmbH. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for immatics biotechnologies GmbH. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
immatics biotechnologies GmbH valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold immatics biotechnologies GmbH, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by immatics biotechnologies GmbH executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming immatics biotechnologies GmbH. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming immatics biotechnologies GmbH. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for immatics biotechnologies GmbH. Press releases and market coverage, newest first.